Charlotte Robinson

DocwireNews

In a third-quarter earnings report, Novo Nordisk revealed that it will terminate development of ocedurenone, a nonsteroidal mineralocorticoid receptor antagonist intended to treat hypertension in chronic kidney disease.
The company halted the phase 3 CLARION-CKD trial of ocedurenone after an interim analysis in June found that the trial had missed its primary endpoint of causing a significant change in systolic blood pressure. Further analysis of detailed trial data led to the decision to end further development of the drug.
While Novo Nordisk reported that its operating profit increased by 21% in Danish kroner and by 22% at constant exchange rates (CER) to DKK 91.6 billion, that number was affected by an impairment loss of DKK 5.7 billion (~$821 million) related to ocedurenone.
Novo Nordisk purchased ocedurenone from KBP Biosciences for $1.3 billion in 2023.

Jordana Jampel

Molecular Structure of Apolipoprotein B100 Discovered

Preventive Cardiology

Laura Litwin

Preventing POAF: Partial Cardiac Denervation After CABG Reduces Incidence Without Increasing Complications

Atrial Fibrillation

Cecilia Brown

EMA CHMP Recommends Durvalumab for Limited-Stage SCLC

Small Cell Lung Cancer

Latest News

Novo Nordisk Drops Ocedurenone After Trial Failure and Financial Losses

Chronic Kidney Disease

Novo Nordisk will terminate development of ocedurenone for treatment of hypertension in chronic kidney disease (CKD).

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe